BioLineRx Breaks Ground in Glioblastoma Treatment with GLIX1
In a major breakthrough for glioblastoma treatment, BioLineRx has announced significant progress on its highly innovative molecule, GLIX1. The company's Chief Executive Officer, Phil Serlin, highlighted the advancements made during their fourth quarter and full year 2025 financial results conference call.
GLIX1 is a first-in-class oral small molecule that selectively targets DNA damage repair in cancer cells only by restoring TET2 activity. This mechanism of action has shown potent antitumor activity and excellent blood-brain barrier penetration, combined with a favorable safety profile in toxicology studies. The FDA approved Hemispherian's Investigational New Drug application for GLIX1 last August, allowing the company to initiate the first-in-human phase I/II-A glioblastoma trial by the end of this month.
The clinical trial aims to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The objectives are to establish a maximum tolerated dose and/or recommended dose based on safety, PK/PD, and preliminary efficacy. Data from the phase I part of the trial are anticipated in the first half of next year.
Phase II-A expansion cohorts will include various population groups, including GBM, both newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. These cohorts are expected to identify preliminary efficacy, PD assessment, and dose optimization data, serving as the basis for a rapid and effective advanced clinical development program.
Three renowned academic centers will participate in this clinical trial: NYU Langone Health, Northwestern University, and Moffitt Cancer Center. In parallel, BioLineRx will continue to conduct preclinical activities in support of further development of GLIX1 in additional cancer indications with high unmet needs.
The company is also conducting studies to investigate the potential synergistic effect of GLIX1 in combination with PARP inhibitors as they work to maximize the value of the GLIX1 opportunity. The significance of this endeavor cannot be overstated, as GBM is the most common and aggressive form of primary brain cancer, with a high unmet need for novel and more effective treatments.
